DHT

Unknown Company

63,500
+0.00%
Mkt Cap 5.8T
Data as of 2026-07-14 · Source: public Vietnamese market feeds

By Aveluro Research Team · Editorial policy

DHT (DHT) is a company in Vietnam's Health Care sector, listed on HNX. The stock last traded at 63,500 VND, little changed on the session, giving a market capitalization of 5.8 trillion VND.

On valuation, DHT trades at a price-to-earnings ratio of 131.2 and a price-to-book of 5.2. That is a premium to the Health Care sector average P/E of 25.9. Return on equity of 3.9% points to weak profitability relative to the company's equity base, below the sector average of 8.1%. Trailing earnings per share stand at 487 VND.

Aveluro tracks 5 news items mentioning DHT, where recent coverage skews negative (40% of articles). The most recent catalyst was a foreign flow event — "Foreign Investors Net Sell VND 562B on June 2, Buy FPT Nearly VND 500B". Aveluro's composite model rates DHT 5.2/10 (Hold), blending news sentiment, price momentum, and fundamentals.

Average daily volume over the past 10 sessions is roughly 6,963 shares; liquidity is relatively thin, so single headlines can move the price sharply. Comparable names in the Health Care sector include AMV, CVN and DAN.

Latest price
63,500 VND · +0.00%
Dominant Sentiment
Negative · 5 Articles Analyzed
Latest catalyst
foreign flow
Liquidity
Low
Data as of
2026-07-14

Foreign Investors Net Sell VND 562B on June 2, Buy FPT Nearly VND 500B

Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.

5.2
Hold
Sentiment
+0.00
Impact
0.50
Momentum
-0.25
Fundamentals
-0.60
Volume
0.00

Want to trade DHT? Compare brokers for Vietnam stocks.

Foreign investors need a broker that can handle Vietnam market access, settlement, custody, and foreign ownership limits.

Aveluro may earn a commission from broker partners. Market data and broker availability can change; confirm access before opening an account.

Unusual volume on 2026-07-07 — 5.1× the 20-day average DHT volume spike details →
10-Session Avg Vol
7.0K
Market Cap
₫5.8T
Liquidity
Low

Low liquidity — thin average daily volume may result in wider spreads and price impact on larger orders.

P/E
131.2
P/B
5.2
ROE
3.9%
ROA
2.5%
EPS
487
Articles Analyzed
5
Dominant Sentiment
Negative
Negative 2
Neutral 2
Positive 1
Full Analysis foreign flow Jun 02, 2026
Foreign Investors Net Sell VND 562B on June 2, Buy FPT Nearly VND 500B

Foreign investors net sold VND 562 billion on June 2, 2026, extending a recent selling trend. The selling was concentrated in HPG, HDB, ACB, CTG, and VPB, while FPT saw net buying of nearly VND 500 billion, making it the top purchased stock on HOSE.

4 -3.5 Negative
Read full analysis →
Full Analysis foreign flow May 27, 2026
Foreign Net Sell VND 800B on May 27: VHM, HPG, VIC, FPT, BSR Hit Hardest

Foreign investors net sold nearly VND 800 billion (USD 31.4 million) on May 27, with VHM (VND 220B), HPG (VND 141B), VIC (VND 102B), FPT (VND 83B), and BSR (VND 51B) bearing the heaviest selling. The sell-off contributed to a 10-point drop in VN-Index to 1,874, while MSB, MWG, and ACB saw net buying.

4 -3.5 Negative
Read full analysis →
Full Analysis sector sentiment May 13, 2026
Foreign Ownership Dominates Vietnam's Top Pharma Stocks: DHG, IMP, DHT

Vietnam's top three pharma companies by market cap—DHG, IMP, and DHT—are now under foreign control or significant influence, with Taisho, Livzon, and ASKA as key shareholders. The sector is projected to double from $8-9 billion to $16 billion by 2032, driving M&A interest.

4 Neutral
Read full analysis →
Full Analysis m a announcement
Chinese Livzon Acquires 67.87% of Imexpharm (IMP) for VND 6,000B in Landmark Pharma M&A

IMP is now majority-owned by China's Livzon after a VND 6,000B deal for 67.87% of shares. The acquisition gives Livzon control of IMP's 12 EU-GMP production lines, a rare asset in Vietnam. The deal underscores a broader trend of foreign domination among top Vietnamese pharma firms, including DHG (Taisho), DMC (Abbott), and DHT (ASKA).

8 Neutral
Read full analysis →

Information provided for educational purposes only. Past performance does not guarantee future results. Data sourced from public Vietnamese market feeds.

Last updated: 2026-07-14T14:00:55Z.

About · Methodology · Editorial Policy · Privacy